Real-time Estimate Cboe Europe  -  03:16 2022-08-16 am EDT
318.18 CHF   +0.09%
01:21aSwiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
01:02aFDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
01:01aFDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Holding AG : There is still some upside potential

03/18/2022 | 02:50am EDT
long trade
Target price hit
Entry price : 362.5CHF | Target : 400CHF | Stop-loss : 330CHF | Potential : 10.34%
Roche Holding AG's shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Investors have an opportunity to buy the stock and target the CHF 400.
Roche Holding AG : Roche Holding AG : There is still some upside potential
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analyst opinion has improved significantly over the past four months.

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's enterprise value to sales, at 4.69 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

© 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Sales 2022 64 249 M 67 994 M 67 994 M
Net income 2022 14 824 M 15 688 M 15 688 M
Net Debt 2022 10 272 M 10 870 M 10 870 M
P/E ratio 2022 17,1x
Yield 2022 3,04%
Capitalization 262 B 278 B 278 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,12x
Nbr of Employees 100 920
Free-Float 82,4%
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 317,90 CHF
Average target price 374,13 CHF
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.14%277 502
JOHNSON & JOHNSON-2.91%434 603
PFIZER, INC.-15.75%281 235
ABBVIE INC.5.09%252 131
NOVO NORDISK A/S4.76%240 550